TMEM223

Across TCGA pan-cancer cohorts, TMEM223 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TMEM223’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TMEM223 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TMEM223 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where TMEM223 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM223 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	−0.284	<.001	8	view →
LUAD	Female	III,IV	+0.598	<.001	7	view →
LSCC	Female	II,III,IV	+0.474	<.001	7	view →
OV	All	All	+0.542	.021	2	view →
PDAC	All	All	−0.269	.028	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TMEM223–CCRCC

Open the CCRCC breakdown →